Early results of a phase I clinical trial suggest that an experimental ALK inhibitor drug will progress to the next phase of testing, researchers reported at the 2013 European Cancer Congress in Amsterdam, Netherlands. Called TSR-011, the new ALK inhibitor shrank tumors or kept them from growing in three people with non-small cell lung cancers that had abnormal ALK genes and that resisted a current ALK inhibitor called crizotinib. The researchers expect that TSR-011 will advance to a phase II trial of NSCLC patients with ALK abnormalities by end of year.